pharmacopeia
GET
/api/v1/drug/dimenhydrinate

Mechanism of action

Sourced from openFDA

Mechanism-of-action class: Histamine H1 Receptor Antagonists.

Histamine H1 Receptor

Indications

Sourced from openFDA
  • Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizzinessICD-10: R11.2

Dosage & administration

Sourced from openFDA

Directions to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity adults and children 12 years and over 1 to 2 tablets every 4-6 hours; do not exceed 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years 1/2 to 1 tablet every 6-8 hours; do not exceed 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years 1/2 tablet every 6-8 hours; do not exceed 1&1/2 tablets in 24 hours, or as directed by a doctor

Warnings & precautions

Sourced from openFDA

Do not use for children under 2 years of age unless directed by a doctor. Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. When using this product marked drowsiness may occur alcohol, sedatives, and tranquilizers may increase drowsiness use caution when driving a motor vehicle or operating machinery avoid alcoholic beverages If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Approval history

Sourced from openFDA
  • Jun 23, 2004ANDAANDA040519Fresenius Kabi Usa

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
10,403 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Nausea2,42123%
  2. 2Fatigue1,80617%
  3. 3Off Label Use1,75917%
  4. 4Headache1,54115%
  5. 5Vomiting1,35713%
  6. 6Malaise1,19411%
  7. 7Dizziness1,10811%
  8. 8Diarrhoea1,09811%
  9. 9Pain1,09110%
  10. 10Drug Ineffective1,08310%
  11. 11Pyrexia9669.3%
  12. 12Cough9168.8%
  13. 13Dyspnoea9138.8%
  14. 14Arthralgia8748.4%
  15. 15Rash8748.4%

Literature

View JSON

Recent PubMed references pinned to Dimenhydrinate as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 220 ClinicalTrials.gov registrations naming Dimenhydrinate as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

How does Dimenhydrinate work?
Mechanism-of-action class: Histamine H1 Receptor Antagonists.
What is Dimenhydrinate used for?
According to FDA labeling, Dimenhydrinate carries indications including: Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Dimenhydrinate?
Dimenhydrinate is classified as Aminoalkyl ethers, Histamine H1 Receptor Antagonists, Decreased Histamine Activity.
What are the brand names for Dimenhydrinate?
Dimenhydrinate is marketed under brand names including Airmit, Dramamine, Driminate, Gravol, TripTone, Wal-Dram.
Note. Data for dimenhydrinate is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients